{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:28Z","timestamp":1786649368654,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Several prognostic scores exist in DLBCL, including the International Prognostic Index (IPI). More recently, a modification of the IPI that estimates the risk of progression to the central nervous system (CNS-IPI) was published. Whether the CNS-IPI index is sufficient to prognosticate DLBCL survival is yet untested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aim to describe the outcomes of DLBCL patients based on CNS-IPI risk groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed all DLBCL cases diagnosed from January 2015 until April 2022 at an academic tertiary hospital in Riyadh, Saudi Arabia. CNS-IPI was calculated at the time of diagnosis. The outcomes were compared between two CNS-IPI risk categories: low and intermediate\/high-risk groups. Logrank method was used to calculate\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value, and Kaplan\u2013Meier method to estimate survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 136 patients were included (median age: 56.5 years), of which 38 (28%) died: 5 in the low-risk group and 33 in the intermediate\/high-risk group. Low-risk and intermediate\/high-risk CNS-IPI were found in 41 (30%) and 95 (70%) patients, respectively. The median survival in the low-risk and intermediate\/high-risk CNS-IPI groups was 66 months [95% CI: 60\u2013not-reached (NR)] and NR (95% CI: 24\u2013NR) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007), respectively. Only seven (5%) patients developed progression to the CNS, of which 6 (86%) were in the intermediate\/high-risk group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The risk of progression to the central nervous system was moderate in our diffuse large B-cell lymphoma population. Patients with intermediate\/high-risk CNS-IPI had worse survival compared with low-risk patients. The CNS-IPI was found to a good model to not only estimate the risk of disease progression to the central nervous system but also overall survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjmms.sjmms_654_24","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:00:10Z","timestamp":1752670810000},"page":"205-209","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Survival and Outcome of Patients with Diffuse Large B-cell Lymphoma According to the Central Nervous System\u2013International Prognostic Index"],"prefix":"10.4103","volume":"13","author":[{"given":"Musa Fares","family":"Alzahrani","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Basahih","sequence":"additional","affiliation":[{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sewaralthahab","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah","family":"Alshalati","sequence":"additional","affiliation":[{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alrumaih","sequence":"additional","affiliation":[{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazi Nur","family":"Asfina","sequence":"additional","affiliation":[{"name":"College of Medicine and Research Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gamal","sequence":"additional","affiliation":[{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjah","family":"Algahtani","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Aleem","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1002\/cam4.3237","article-title":"Recent survival trends in diffuse large B-cell lymphoma \u2013 Have we made any progress beyond rituximab?","volume":"9","author":"Epperla","year":"2020","journal-title":"Cancer Med"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R\u2013IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal diffuse large B cell lymphoma: Molecular features, prognosis, and risk of central nervous system recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3324\/haematol.2019.229948","article-title":"Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: A systematic review","volume":"105","author":"Eyre","year":"2020","journal-title":"Haematologica"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: A multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.2021012888","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: Real-world outcomes from 21 US academic institutions","volume":"139","author":"Orellana-Noia","year":"2022","journal-title":"Blood"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am J Hematol"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J"},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-021-00535-y","article-title":"High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma","volume":"11","author":"Ong","year":"2021","journal-title":"Blood Cancer J"},{"key":"R15-20260421","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12185-019-02653-7","article-title":"Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: A prospectively collected, single-center cohort analysis","volume":"110","author":"Lee","year":"2019","journal-title":"Int J Hematol"},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1080\/10428194.2018.1564823","article-title":"Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse","volume":"60","author":"Goldschmidt","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R17-20260421","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","article-title":"The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy","volume":"75","author":"El-Galaly","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_654_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:14Z","timestamp":1786647194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_654_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_654_24","relation":{},"ISSN":["1658-631X","2321-4856"],"issn-type":[{"value":"1658-631X","type":"print"},{"value":"2321-4856","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-10-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}